Roche's obesity drug petrelintide shows positive results in Phase II clinical trials

LootboxPhobia · 2026-03-05T21:50:54+00:00

Roche Holdings announced positive results from its Phase II clinical trial of the obesity treatment drug petrelintide, with patients losing an average of 10.7% of their weight within 42 weeks. No serious side effects were observed during the trial, and Roche plans to initiate a combined treatment trial with CT-388 in 2026.

LootboxPhobia

2026-03-05 21:50:54

Abstract generation in progress

Investing.com – Roche Holdings (SIX:ROG) announced that its Phase II clinical trial for the glucagon-like peptide-1 analog petrelintide, used to treat overweight and obesity, has shown positive results.

The trial demonstrated an average weight loss of 10.7% at week 42. The company reported that at the maximum effective dose of petrelintide, there were no cases of vomiting or treatment discontinuation due to gastrointestinal issues.

Roche stated that it plans to initiate a Phase II trial combining petrelintide with CT-388 later in 2026.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.